Apogee falls following phase 2 results for zumilokibart in atopic dermatitis
Apogee Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $79.30
-1.2% in 1d after detection
Post-detection moves
1h
-1.0%
1d
-1.2%
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS